SIGLEC10 and neoplasm: To characterize the precise effects of OAds, we evaluated antitumor activity in three tumor models established with immunocompetent mice treated with an intratumoral injection of OAd-null, OAd-SIRPα-Fc, OAd-Siglec10-Fc, or OAd-TIGIT-Fc.